Brand new data from Phase I and translational studies to be presented at ENA2018

The 30th edition of EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics (ENA2018) will be held in Dublin from 13-16 November 2018. The meeting again will present new data for molecular targets and drug development.

This meeting focuses on immuno-oncology and a critical understanding of the constant tension between evolving cancer genome and the tumour microenvironment in which it resides and its therapeutic impact,” said Professor Charles Swanton, ENA 2018 Scientific Chairman and Medical Oncologist from the Francis Crick Institute in London, UK. “Hence, it is mandatory to have full breadth of cancer research and its clinical implications. “We are very happy to present studies showing therapeutic indications, showcasing data that has never been presented before.”

These include:

MammaPrint High1/High2 risk class as a pre-specified biomarker of response to nine different targeted agents plus standard neoadjuvant therapy for ~ 1000 breast cancer patients in the I-SPY 2 TRIAL

BluePrint basal subtype predicts neoadjuvant therapy response in ~400 HR+HER2- patients across 8 arms in the I-SPY 2 TRIAL

Speaker: Laura van’t Veer, USA

Pharmacology of oral (PO) Ropidoxuridine in treating patients with advanced gastrointestinal cancer undergoing radiation therapy (RT) (NCT02381561)

Speaker: Timothy Kinsella, USA

Activity and safety of ibrutinib and durvalumab in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)

Speaker: Alex Herrera, USA

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers

Speaker: Muralidhar Beeram, USA

Phase I dose-finding study of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (pts) with advanced malignancies

Speaker: Oliver  Bechter, Belgium

Phase I/II study of the A2AR antagonist NIR178 (PBF-509) combined with the anti-PD-1 monoclonal antibody spartalizumab in patients with advanced NSCLC

Speaker: Alberto Chiappori, USA

ADVL1515: Phase 1 Study of Prexasertib (LY2606368), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors: A Report from the Children’s Oncology Group Phase 1/Pilot Consortium

Speaker: Cynthia Wetmore, USA

Proof-of-Mechanism Based on Target Engagement and Modulation of Gene Expression Following Treatment with SY-1365, a First-in-Class Selective CDK7 Inhibitor in Phase 1 Patients with Advanced Cancer

Speaker: Dejan Juric, USA

Preliminary results from a Phase Ib study of pixatimod (PG545) in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer

Speaker: Darryn Bampton, Australia

AZD5363 in Patients (Pts) with Tumors with AKT Mutations: NCI-MATCH Subprotocol EAY131-Y, A Trial of the ECOG-ACRIN Cancer Research Group

Speaker: Kevin Kalinsky, USA

In addition to these selected abstracts, there are number open slots for late breaking abstracts; submission will be open for these abstracts from 21-28 September 2018. The submission information can be found here.

As well as an international audience of leading clinicians and researchers, the conference will have an extensive media programme attracting healthcare and scientific journalists from round the world, therefore maintaining the conference’s global outreach.

“This year, we have a very exciting programme, I’m particularly looking forward to learning about the interface between the tumour metabolome and the immune microenvironment,” said Professor Swanton. “Also, I look forward to the Michel Clavel lecture presented by Professor Julian Downward. In many ways, Julian is the unsung hero of the RASEGFR signalling pathway. In his PHD with Mike Waterfield, he discovered the epidermal growth factor receptor, which as everybody now knows represents a key therapeutic opportunity in lung cancer, and its close relatives, HER-2, and HER-3 in breast cancer. Julian has mapped out this pathway in its entirety over the last two decades and contributed profoundly to the knowledge of how cells operates in health and in disease. He is one of the most accomplished, thoughtful and outstanding scientists in his generation and it will be a real honour to host him at ENA 2018.”

“There are a lot of interesting sessions lead by a world renowned faculty. Join us for this truly innovative meeting and be the first to learn about the new therapeutic advances in cancer.”

Click here for more information about ENA2018.

Back to news list